These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9574467)

  • 1. Role of dyslipidemia in the progression of chronic renal disease.
    Cappelli P; Di Liberato L; Albertazzi A
    Ren Fail; 1998 Mar; 20(2):391-7. PubMed ID: 9574467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-3 polyunsaturated fatty acid supplementation in chronic progressive renal disease.
    Cappelli P; Di Liberato L; Stuard S; Ballone E; Albertazzi A
    J Nephrol; 1997; 10(3):157-62. PubMed ID: 9238624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipids in the progression of chronic renal failure.
    Cappelli P; Evangelista M; Bonomini M; Palmieri PF; Albertazzi A
    Nephron; 1992; 62(1):31-5. PubMed ID: 1436288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
    Ruggenenti P; Perna A; Mosconi L; Pisoni R; Remuzzi G
    Kidney Int; 1998 May; 53(5):1209-16. PubMed ID: 9573535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipids and apolipoproteins change during the progression of chronic renal failure.
    Bergesio F; Monzani G; Ciuti R; Serruto A; Benucci A; Frizzi V; Salvadori M
    Clin Nephrol; 1992 Nov; 38(5):264-70. PubMed ID: 1451339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure.
    Sechi LA; Zingaro L; Catena C; Perin A; De Marchi S; Bartoli E
    Kidney Int; 1999 Sep; 56(3):1049-57. PubMed ID: 10469373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-dialysis retention of blood lipoproteins and apolipoproteins in patients with end-stage renal disease on maintenance haemodialysis in Kuwait.
    Al-Rashidi M; Hussain AA; Nampoory MR; Al-Ali JH; Akanji AO
    Clin Chim Acta; 2004 Jun; 344(1-2):149-54. PubMed ID: 15149883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of serum lipid abnormalities in chronic nephritis.
    Hirano H; Yamada Y; Otani H; Kodama N; Mune M; Yukawa S
    Kidney Int Suppl; 1999 Jul; 71():S147-9. PubMed ID: 10412761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Factors in the progression of renal insufficiency during the 2 years preceding the use of dialysis].
    Kacso I; Gherman M; Mazouz H; Ghazali A; el Esper N; Morinière P; Makdassi R; Hardy P; Westeel PF; Achard JM; Pruna A; Fournier A
    Nephrologie; 1999; 20(1):19-28. PubMed ID: 10081033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients.
    Fytili CI; Progia EG; Panagoutsos SA; Thodis ED; Passadakis PS; Sombolos KI; Vargemezis VA
    Ren Fail; 2002 Sep; 24(5):623-30. PubMed ID: 12380908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
    Navarro JF; Mora C; Muros M; García-Idoate G
    Nephron Clin Pract; 2003; 95(4):c128-35. PubMed ID: 14694274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum lipids and apolipoproteins A-I, A-II, and B in hyperthyroidism before and after treatment.
    Muls E; Blaton V; Rosseneu M; Lesaffre E; Lamberigts G; De Moor P
    J Clin Endocrinol Metab; 1982 Sep; 55(3):459-64. PubMed ID: 6808006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidaemia and the progression of renal disease in chronic renal failure patients.
    Massy ZA; Nguyen Khoa T; Lacour B; Descamps-Latscha B; Man NK; Jungers P
    Nephrol Dial Transplant; 1999 Oct; 14(10):2392-7. PubMed ID: 10528663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
    Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
    Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.
    Attman PO; Alaupovic P; Tavella M; Knight-Gibson C
    Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression rate to end-stage renal failure in non-diabetic kidney diseases: a multivariate analysis of determinant factors.
    Jungers P; Hannedouche T; Itakura Y; Albouze G; Descamps-Latscha B; Man NK
    Nephrol Dial Transplant; 1995; 10(8):1353-60. PubMed ID: 8538926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
    Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P
    Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is arterial hypertension an underlying factor in the increased serum Lp(a) levels in ESRD dialyzed patients?
    Fytili CI; Passadakis PS; Progia EG; Kambouromiti GL; Panopoulou MI; Sombolos KI; Vargemezis VA
    Ren Fail; 2002 Sep; 24(5):631-8. PubMed ID: 12380909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoproteins and apolipoproteins during the progression of chronic renal disease.
    Grützmacher P; März W; Peschke B; Gross W; Schoeppe W
    Nephron; 1988; 50(2):103-11. PubMed ID: 3221949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of lipid parameters and bioindices in patients with different stages of chronic renal failure.
    Cabarkapa V; Djerić M; Stosić Z; Sakac V; Zagorka LC; Vucković B
    Vojnosanit Pregl; 2012 Nov; 69(11):961-6. PubMed ID: 23311247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.